Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 11/20 | 0.44 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.40 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.40 |
| ▸ | HTR3B | O95264 | 1/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.40 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.40 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1672516 | 0.90 | HTR3A (0.43) | HTR3AHTR3ESLC22A2HTR3BCHRNB2 | |
| Lithium Ion SCHEMBL699921 | 0.89 | HTR3A (0.42) | HTR3AHTR3ESLC22A2HTR3BCHRNB2 | |
| SCHEMBL702139 | 0.77 | CHRM2 (0.48) | — | |
| SCHEMBL702138 | 0.77 | CHRM2 (0.48) | — | |
| SCHEMBL702645 | 0.77 | CHRM2 (0.48) | — | |
| SCHEMBL701218 | 0.76 | HTR3A (0.54) | HTR3AHTR3ESLC22A2HTR3BCHRNB2 | |
| SCHEMBL28440766 | 0.72 | NR4A2 (0.50) | — | |
| SCHEMBL701688 | 0.71 | HTR3A (0.48) | HTR3AHTR3ESLC22A2HTR3BCHRNB2 | |
| SCHEMBL701546 | 0.71 | NR4A2 (0.39) | — | |
| SCHEMBL28451302 | 0.71 | NR4A2 (0.51) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8710047-B2 | 5-HT3 receptor modulators, methods of making, and use thereof | ALBANY MOLECULAR RESEARCH, INC. (US) | 2014-04-29 | — | — | US | disclosed |
| US-20130310366-A1 | 5-HT3 RECEPTOR MODULATORS, METHODS OF MAKING, AND USE THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2013-11-21 | — | — | US | disclosed |
| US-8501729-B2 | 5-HT3 receptor modulators, methods of making, and use thereof | ALBANY MOLECULAR RESEARCH, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| US-20120219641-A1 | 5-HT3 RECEPTOR MODULATORS, METHODS OF MAKING, AND USE THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-08-30 | — | — | US | disclosed |
| US-8124600-B2 | 5-HT3 receptor modulators, methods of making, and use thereof | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-20090298809-A1 | 5-HT3 RECEPTOR MODULATORS, METHODS OF MAKING, AND USE THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130310366-A1 | 5-HT3 RECEPTOR MODULATORS, METHODS OF MAKING, AND USE THEREOF | HTR3A, HTR5A, HTR3B | HTR3A 1/4885HTR3E 5/4885SLC22A2 3109/4885 |
| US-20090298809-A1 | 5-HT3 RECEPTOR MODULATORS, METHODS OF MAKING, AND USE THEREOF | HTR3A, HTR5A, HTR3B | HTR3A 1/4885HTR3E 5/4885SLC22A2 3109/4885 |
| US-20120219641-A1 | 5-HT3 RECEPTOR MODULATORS, METHODS OF MAKING, AND USE THEREOF | HTR3A, HTR5A, HTR3B | HTR3A 1/4885HTR3E 5/4885SLC22A2 3109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.